>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

  • KN +15.2%, TWTR +14.6%, XLNX +12.3%, TSLA +10.3%, ECHO +9.3%, CVRR +8.8%, MLNX +7.9%, SNBR +7.9%, FTI +5.7%, FFIV +5.2%, ELY +4.2%, LYG +4.2%, CMCSA +4.2%, IRM +3.9%, CPG +3.8%, AAL +3.8%, F +3.7%, WHR +3.6%, ICLR +3.6%, PS +3.3%, RTN +3.2%, VLO +3.2%, VALE +3.1%, MSFT +2.9%, IP +2.7%, CELG +2.7%, UBS +2.6%, AEM +2.5%, VC +2.3%, NOW +2.2%, CEO +2.2%, SHOP +2.1%, V +2%, SAVE +1.9%, CTXS +1.9% (also authorizes $750 million increase to share repurchase program), NRZ +1.9%, BMY +1.7%, DLB +1.5%, AXTA +1.4%, MRK +1.4%, COP +1.2%, HPE +1.1%, VRTX +1.1%, MANH +1.1%, IRDM +1.1%

Other news:

  • NDLS +13.4% (elects to not pursue offering of up to 10,062,500 shares of its Class A common stock at this time due to market conditions)
  • MRVL +3.3% (Starboard increases active stake to 5.9% (Prior 5.2%), releases presentation given at Capitalize for Kids Investors Conference )
  • NOG +2.6% (continued weakness - down 16% on the week)
  • INCY +2% (FDA accepts for Priority Review the sNDA for ruxolitinib for patients with acute graft-versus-host disease)
  • TWLO +1.6% (names Khozema Shipchandler as CFO effective Nov. 12, 2018; note stock closed 8% lower on the day)
  • KLAC +1.3% (plans to establish a research and development center in Ann Arbor)
  • REGN +1.2% (announces Phase 3 PANORAMA trial evaluating EYLEA injections met one-year primary and key secondary endpoints; provides regulatory update on EYLEA pre-filled syringe)
  • DXC +1% ( continued volatility on well above-average volumes amid rumors of the exit of a member of co's management; co subsequently made a statement affirming guidance at high end of prior)

Analyst comments:

  • YPF +6.3% (upgraded to Outperform from Neutral at Credit Suisse)
  • HLT +5.1% (upgraded to Buy from Neutral at B. Riley FBR)
  • TOL +3.5% (upgraded to Outperform from In-Line at Evercore ISI)
  • CHGG +2.9% (upgraded to Buy from Neutral at Citigroup)
  • NSC +1.8% (upgraded to Buy from Hold at TD Securities)
  • OC +0.7% (upgraded to Overweight from Equal Weight at Barclays)